Neoangiogenesis promotion

Neoangiogenesis promotion is a complex biological process involving the formation of new blood vessels from existing vasculature, driven by a balance of pro-angiogenic and anti-angiogenic factors [1][2]. In physiological contexts, it is essential for embryonic development, the menstrual cycle, and wound repair [11]. In pathological states, particularly cancer, the 'angiogenic switch' is triggered, leading to the overexpression of factors like Vascular Endothelial Growth Factor (VEGF) and Fibroblast Growth Factor (FGF), which promote tumor neovascularization to sustain growth and facilitate metastasis [2][4]. This process is a major focal point for pharmacological intervention; anti-angiogenic drugs such as bevacizumab (a monoclonal antibody targeting VEGF) and multi-kinase inhibitors like sunitinib and sorafenib are widely used to inhibit neoangiogenesis in solid tumors [4][5]. Conversely, pro-angiogenic therapies aim to stimulate this process in patients with ischemic diseases or chronic wounds to restore blood flow [6][8]. Safety concerns associated with inhibiting this process include hypertension, hemorrhage, and impaired wound healing, while unintended promotion can lead to disease progression [1][10].

Other names

Angiogenesis stimulationNeovascularization inductionPro-angiogenic activityTherapeutic angiogenesisAngiogenesis promotion

Modulation of angiogenic signaling pathways, primarily through the inhibition of the VEGF/VEGFR axis in oncology or the stimulation of growth factor pathways (e.g., PDGF, FGF) in regenerative medicine.